News Four more drugs in keenly watched ALS trial miss the mark ALS candidates from Biohaven, Prilenia, Clene, and UCB were unable to slow disease progression in the study, but two showed signs of efficacy.
News Prilenia eyes 2025 launch for Huntington’s drug pridopidine Prilenia Therapeutics is planning to file its Huntington’s disease therapy pridopidine in the EU, despite mixed results in a phase 3 trial.